advertisement
Abstract #27892 Published in IGR 13-1
Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration
Kawase K; Yamamoto T; Muramatsu T; Ono J; Nakajima T; Matsuhisa A; Sugiura T; Migita M; Ishikawa YNippon Ganka Gakkai Zasshi 2010; 114: 976-982
We investigated the effectiveness, safety and plasma concentration of long-acting carteolol hydrochloride 2% ophthalmic solution (LA) as compared with the original carteolol hydrochloride 2% ophthalmic solution(CA). Patients with primary open angle glaucoma and ocular hypertension were randomized to 62 patients of LA group (LA once a day) and 62 patients of CA group (CA twice a day) in this multicenter, open-label trial. The intraocular pressure (IOP), pulse rate, blood pressure and plasma concentration were examined for 8 weeks. The IOP reduction and reduction rate were not significant at any point between the two groups. Systolic blood pressure decreased significantly in both groups, however, diastolic blood pressure decreased only in the CA group. The plasma concentration of the LA group was significantly lower than that of the CA group. The IOP reduction effect of the LA group was the same as the CA group. This study suggests that long-acting treatment with alginic acid can be useful for reducing systemic side effects. LA: Japanese
K. Kawase. Department of Ophthalmology, Gifu University School of Medicine, 1-1 Yanagido, Gifu-shi, Gifu-ken 501-1194, Japan. mekawase@gifu-u.ac.jp
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
